List of Oxtellar Xr drug patents

Oxtellar Xr is owned by Supernus Pharms.

Oxtellar Xr contains Oxcarbazepine.

Oxtellar Xr has a total of 10 drug patents out of which 0 drug patents have expired.

Oxtellar Xr was authorised for market use on 19 October, 2012.

Oxtellar Xr is available in tablet, extended release;oral dosage forms.

Oxtellar Xr can be used as treatment of partial-onset seizures.

The generics of Oxtellar Xr are possible to be released after 13 April, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220042 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US9119791 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US7910131 SUPERNUS PHARMS Method of treating seizures using modified release formulations of oxcarbazepine
Apr, 2027

(4 years from now)

US9855278 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US11166960 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US8821930 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US9351975 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US7722898 SUPERNUS PHARMS Modified-release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US8617600 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

US9370525 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof
Apr, 2027

(4 years from now)

Drugs and Companies using OXCARBAZEPINE ingredient

Market Authorisation Date: 19 October, 2012

Treatment: Treatment of partial-onset seizures

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of OXTELLAR XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic